MERRIMACK PHARMACEUTICALS INC (MACK) [Rocket]

Overview

MERRIMACK PHARMACEUTICALS INC (MACK)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
08/14/2023	4	CROCKER GARY L (See Remarks) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC
08/14/2023	SC 13D/A	Western Standard LLC reports a 13.9% stake in Merrimack Pharmaceuticals, Inc.
08/09/2023	4	Andersen Eric (Director) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC
08/03/2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/03/2023	10-Q	Quarterly Report for the period ended June 30, 2023
06/08/2023	4	Radeljevic Ana (Director) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC
06/08/2023	4	Nielsen Ulrik B. (Director) has filed a Form 4 on MERRIMACK PHARMACEUTICALS INC

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	0.0	0.0	7.9	27.3	0.0	0.0	0.0	0.0
Revenue growth		-100.0%	-71.1%					-100.0%
Cost of goods sold	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	5.0	27.3	0.0	0.0	0.0	0.0
Gross margin			63.6%	100.0%
Selling, general and administrative	1.7	2.5
Research and development				11.1	50.0	67.3	109.6	121.0
General and administrative			5.0	16.2	15.6	28.5	32.1	24.0
EBIT	0.0	0.0	-2.9	-22.4	-65.6	-84.9	-141.6	-145.1
EBIT margin			-36.4%	-82.0%
Pre-tax income	-1.5	-2.5	-3.0	-22.7	-68.5	-118.4	-169.5	-162.8
Income taxes	0.0	0.0	0.0	-1.5	-7.7	-42.4	-13.2	-11.2
Tax rate			0.5%	6.5%	11.2%	35.8%	7.8%	6.9%
Earnings from continuing ops			-3.0	-25.2	-81.0	-74.8	-310.8	-303.4
Earnings from discontinued ops				3.9	20.3	546.9	2.8	3.8
Net income	0.0	0.0	-3.0	-21.3	-60.8	472.0	-308.0	-299.6
Net margin			-38.4%	-78.0%

Diluted EPS	$0.00	$0.00	($0.23)	($1.89)	($6.07)	($5.66)	($24.80)	($27.25)
Shares outstanding (diluted)	13.5	13.4	13.4	13.4	13.3	13.2	12.5	11.1

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.